Others

CAT # Product Name Description
CPD0201 BI1744-HCl BI1744 is a long acting β2-adrenoceptor agonist with an EC50 of 1.4±0.08 nM.
PCO371 Parathyroid hormone (PTH) is essential for calcium homeostasis and its action is mediated by the PTH type 1 receptor (PTHR1), a class B G-protein-coupled receptor. Hypoparathyroidism and osteoporosis can be treated with PTH injections; however, no orally effective PTH analogue is available.
Baloxavir Baloxavir is an anti-influenza agent extracted from patent WO 2017104691 A1.
Mirogabalin besylate
Resmetirom Resmetirom, or MGL-3196, shows outstanding safety in a rat heart model and is efficacious in a preclinical model at doses that showed no impact on the central thyroid axis.
CPDD1578 CU-CPT-8m
CPDD2004 CU-CPT-9b
CPDD1577 CU-CPT-9a
CPDD2044 Vardenafil Vardenafil, also known as BAY 38-9456, is a PDE5 inhibitor used for treating erectile dysfunction.
CPDD2043 Etoricoxib Etoricoxib is a synthetic, nonsteroidal anti-inflammatory drug (NSAID) with antipyretic, analgesic, and potential antineoplastic properties.
CPDD2041 Sildenafil Citrate Sildenafil, Citrate is a citrate form of Sildenafil. Sildenafil is a selective inhibitor of PDE5 (type 5 cGMP phosphodiesterase) which catalyzes the hydrolysis of 3',5'-cyclic guanosine monophosphate (cGMP).
CPDD1640 BMS-986195 BMS-986195 is a potent, covalent, irreversible inhibitor of Bruton’s tyrosine kinase (BTK), a member of the Tec family of non-receptor tyrosine kinases essential in antigen-dependent B-cell signaling and function.
CPD1562 PZM-21 PZM21 is a potent and selective μ opioid receptor agonist with an EC50 of 1.8 nM.
CPDD1626 AZD-7594 AZD-7594, also known as AZ13189620, is an inhaled selective glucocorticoid receptor (GCCR) modulator.
CPDD1644 PRN1008 PRN1008 is a potent, selective and reversible covalent inhibitor of BTK ((IC50 = 1.3 ± 0.5 nM).) with extended PD effects in vivo.
CPDD0995 Bardoxolone methyl The synthetic oleanane triterpenoid CDDO (Item No. 81035) is a Nrf2 activator that inhibits proliferation and induces differentiation and apoptosis in various cancer cells.
CPD1549 Tropifexor Tropifexor is a novel and highly potent agonist of FXR with an EC50 of 0.2 nM.
CPDB3744 Ozanimod Ozanimod (RPC1063) is a novel, oral, once daily, selective sphingosine 1-phosphate 1 and 5 receptor modulator in development for autoimmune indications including relapsing multiple sclerosis (RMS) and ulcerative colitis (UC).
CPD1068 AKP-11 AKP-11 is a S1P1 agonist with immunomodulatory activities.
CPD1017 Bardoxolone Bardoxolone is a novel nuclear regulator factor (Nrf-2) activator.
CPD1122 Mirogabalin Mirogabalin (DS-5565) is a novel, preferentially selective α2δ-1 ligand characterized by high potency and selectivity to the α2δ-1 subunit of voltage-sensitive calcium channel complexes in the CNS.
CPDD1550 GW-870086 GW-870086 is a glucocorticoid receptor agonist potentially for the treatment of asthma and atopic dermatitis.
CPDD9951 Batefenterol Batefenterol is a muscarinic antagonist and β2-adrenergic receptor (β2-AR) agonist (Kis = 1.4, 1.3, and 3.7 nM, for hM2, hM3, and hβ2-AR, respectively in a radioligand binding assay).
CPDD3721 BEC HCl BEC, also known as S-(2-boronoethyl)-L-cysteine, is an a slow-binding and competitive Arginase II inhibitor with Ki of 0.31 μM (ph 7.5). BEC significantly enhances NO-dependent relaxation of human penile corpus canvernosum smooth muscle in vitro at concentrations between 0.1-1.0 mM. S-(2-boronoethyl)-L-cysteine binds to arginase as a transition state analogue and enhances smooth muscle relaxation in human penile corpus cavernosum.


Contact Us

Inquiry

Latest News

  • Top 7 Trends In Pharmaceutical Research In 2018

    Top 7 Trends In Pharmaceutical Research I...

      Being under ever-increasing pressure to compete in a challenging economic and technological environment, pharmaceutical and biotech companies must continually innovate in their R&D programmes to stay ahead ...

  • ARS-1620: A promising new inhibitor for KRAS-mutant cancers

    ARS-1620: A promising new inhibitor for K...

    According to a study published in Cell, researchers have developed a specific inhibitor for KRASG12C called ARS-1602 that induced tumor regression in mice. “This study provides in vivo evidence that mutant KRAS can be...

  • AstraZeneca receives regulatory boost for oncology drugs

    AstraZeneca receives regulatory boost for...

    AstraZeneca received a double boost for its oncology portfolio on Tuesday, after US and European regulators accepted regulatory submissions for its drugs, the first step towards winning approval for these medicines. ...

WhatsApp Online Chat !